|Bid||7.21 x 1000|
|Ask||7.29 x 1800|
|Day's range||7.11 - 7.24|
|52-week range||5.61 - 25.66|
|Beta (5Y monthly)||1.68|
|PE ratio (TTM)||N/A|
|Earnings date||06 Nov 2023 - 10 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||20.60|
The rollout of new COVID-19 vaccines is being obstructed by insurance and supply roadblocks, as customers experience issues with getting insurers to agree on vaccine coverage. The Department of Health and Human Services wrote a letter to insurers stating, "Your obligation as a plan or issuer to ensure that your members have coverage for COVID-19 vaccines without cost sharing is not conditional upon parties' compliance." Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Moderna (NASDAQ: MRNA) recently gave an update on its pipeline and future goals, and the biotech had a lot to say. This doesn't mean Moderna is forgetting about the coronavirus vaccine though. In fact, this market giant announced something that could impact smaller rival Novavax (NASDAQ: NVAX).
In the volatile world of stock trading, healthcare companies Novavax (NASDAQ:NVAX) and Invitae (NYSE:NVTA) have been making headlines as they navigate significant financial challenges. Both firms are taking measures to reduce costs, aiming to improve their financial standing and appeal to a broader range of investors.